CA2914662C - Compositions and methods for treating anemia - Google Patents

Compositions and methods for treating anemia Download PDF

Info

Publication number
CA2914662C
CA2914662C CA2914662A CA2914662A CA2914662C CA 2914662 C CA2914662 C CA 2914662C CA 2914662 A CA2914662 A CA 2914662A CA 2914662 A CA2914662 A CA 2914662A CA 2914662 C CA2914662 C CA 2914662C
Authority
CA
Canada
Prior art keywords
compound
formula
certain embodiments
level
hif
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2914662A
Other languages
English (en)
French (fr)
Other versions
CA2914662A1 (en
Inventor
Robert Shalwitz
Charlotte HARTMAN
Akshay BUCH
Isaiah SHALWITZ
John JANUSZ
Joseph Gardner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Akebia Therapeutics Inc
Original Assignee
Akebia Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52022903&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2914662(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Akebia Therapeutics Inc filed Critical Akebia Therapeutics Inc
Priority to CA3151685A priority Critical patent/CA3151685A1/en
Publication of CA2914662A1 publication Critical patent/CA2914662A1/en
Application granted granted Critical
Publication of CA2914662C publication Critical patent/CA2914662C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pyridine Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA2914662A 2013-06-13 2014-06-04 Compositions and methods for treating anemia Active CA2914662C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA3151685A CA3151685A1 (en) 2013-06-13 2014-06-04 Compositions and methods for treating anemia

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201361834808P 2013-06-13 2013-06-13
US61/834,808 2013-06-13
US201361889478P 2013-10-10 2013-10-10
US61/889,478 2013-10-10
US201361898885P 2013-11-01 2013-11-01
US201361898890P 2013-11-01 2013-11-01
US61/898,885 2013-11-01
US61/898,890 2013-11-01
US201361912185P 2013-12-05 2013-12-05
US61/912,185 2013-12-05
PCT/US2014/040889 WO2014200773A2 (en) 2013-06-13 2014-06-04 Compositions and methods for treating anemia

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA3151685A Division CA3151685A1 (en) 2013-06-13 2014-06-04 Compositions and methods for treating anemia

Publications (2)

Publication Number Publication Date
CA2914662A1 CA2914662A1 (en) 2014-12-18
CA2914662C true CA2914662C (en) 2022-05-31

Family

ID=52022903

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2914662A Active CA2914662C (en) 2013-06-13 2014-06-04 Compositions and methods for treating anemia
CA3151685A Pending CA3151685A1 (en) 2013-06-13 2014-06-04 Compositions and methods for treating anemia

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA3151685A Pending CA3151685A1 (en) 2013-06-13 2014-06-04 Compositions and methods for treating anemia

Country Status (37)

Country Link
US (2) US11857543B2 (https=)
EP (2) EP3007695B1 (https=)
JP (6) JP2016521747A (https=)
KR (4) KR20240055172A (https=)
CN (3) CN114404413A (https=)
AU (4) AU2014278543B2 (https=)
BR (1) BR112015031027A2 (https=)
CA (2) CA2914662C (https=)
CL (2) CL2015003602A1 (https=)
CY (2) CY1126699T1 (https=)
DK (1) DK3007695T3 (https=)
DO (1) DOP2015000297A (https=)
EC (1) ECSP20058592A (https=)
ES (1) ES2974273T3 (https=)
FI (2) FI3007695T3 (https=)
FR (1) FR24C1025I2 (https=)
HR (1) HRP20240319T1 (https=)
HU (2) HUE066123T2 (https=)
IL (3) IL243047B (https=)
LT (2) LT3007695T (https=)
MX (3) MX391198B (https=)
MY (1) MY204336A (https=)
NL (1) NL301278I2 (https=)
NO (1) NO2024025I1 (https=)
NZ (3) NZ714963A (https=)
PE (2) PE20160194A1 (https=)
PH (2) PH12015502738B1 (https=)
PL (1) PL3007695T3 (https=)
PT (1) PT3007695T (https=)
RS (1) RS65341B1 (https=)
RU (2) RU2019134558A (https=)
SG (2) SG10201910773VA (https=)
SI (1) SI3007695T1 (https=)
SM (1) SMT202400092T1 (https=)
TW (4) TWI791177B (https=)
WO (1) WO2014200773A2 (https=)
ZA (1) ZA201509024B (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0713350B1 (pt) 2006-06-26 2022-04-12 Akebia Therapeutics Inc Composto, e, composição
NO2686520T3 (https=) 2011-06-06 2018-03-17
CN105338894B (zh) 2013-04-16 2018-11-30 皇家飞利浦有限公司 用于体表ecg中的双心室起搏器脉冲检测的系统和方法
SG10201910773VA (en) 2013-06-13 2020-01-30 Akebia Therapeutics Inc Compositions and methods for treating anemia
AR099354A1 (es) 2013-11-15 2016-07-20 Akebia Therapeutics Inc Formas sólidas de ácido {[5-(3-clorofenil)-3-hidroxipiridin-2-carbonil]amino}acético, composiciones, y sus usos
AU2016209126A1 (en) 2015-01-23 2017-08-10 Akebia Therapeutics, Inc. Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof
US11324734B2 (en) * 2015-04-01 2022-05-10 Akebia Therapeutics, Inc. Compositions and methods for treating anemia
WO2018103600A1 (zh) * 2016-12-06 2018-06-14 深圳市塔吉瑞生物医药有限公司 一种取代的杂芳基酰胺化合物及包含该化合物的组合物及其用途
WO2019028150A1 (en) 2017-08-01 2019-02-07 Akebia Therapeutics, Inc. COMPOSITIONS FOR USE IN METHODS OF TREATING HEMOGLOBINOPATHIES
EP3790863A1 (en) 2018-05-09 2021-03-17 Akebia Therapeutics Inc. Process for preparing 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetic acid
WO2021087144A1 (en) * 2019-10-31 2021-05-06 Akebia Therapeutics, Inc. Therapeutic methods using vadadustat
US11524939B2 (en) 2019-11-13 2022-12-13 Akebia Therapeutics, Inc. Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid
WO2021186356A1 (en) * 2020-03-17 2021-09-23 Cadila Healthcare Limited Formulation comprising hif prolyl hydroxylase inhibitors
TW202206065A (zh) * 2020-04-29 2022-02-16 美商百愛及生物醫藥公司 用以治療老化相關病況之缺氧誘導因子脯胺醯羥化酶抑制劑
KR20230027157A (ko) 2020-06-19 2023-02-27 아케비아 테라퓨틱스 인코포레이티드 바다두스타트의 약물-약물 상호작용의 조절
WO2022150623A1 (en) 2021-01-08 2022-07-14 Akebia Therapeutics, Inc. Compounds and composition for the treatment of anemia
WO2022150621A1 (en) 2021-01-08 2022-07-14 Akebia Therapeutics, Inc. Therapeutic methods using vadadustat
EP4301352A1 (en) * 2021-03-01 2024-01-10 Akebia Therapeutics Inc. Modulation of drug-drug interactions of vadadustat
WO2022195532A1 (en) 2021-03-19 2022-09-22 Zydus Lifesciences Ltd. Treatment for sickle cell anaemia

Family Cites Families (129)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3655679A (en) 1969-06-25 1972-04-11 Merck & Co Inc Certain aryl pyridine carboxylic acid derivatives
US3703582A (en) 1970-04-20 1972-11-21 Merck & Co Inc Aryl pyridine carboxylic acids in the treatment of inflammation
US3894920A (en) 1971-12-21 1975-07-15 Sagami Chem Res Process for preparing alkyl-substituted 3,6-dihydro-o-dioxin derivatives
US4016287A (en) 1972-07-17 1977-04-05 Boehringer Ingelheim Gmbh Dermatological compositions containing an acylamino-carboxylic acid or an alkyl ester thereof
CA1261335A (en) 1984-08-29 1989-09-26 Hoffmann-La Roche Limited/Hoffmann-La Roche Limitee Ethylenediamine monoamide derivatives
CN1023479C (zh) 1985-09-27 1994-01-12 弗·哈夫曼-拉罗切有限公司 乙二胺的单酰胺衍生物的制备方法
TW219933B (https=) 1990-02-26 1994-02-01 Lilly Co Eli
US5405613A (en) 1991-12-11 1995-04-11 Creative Nutrition Canada Corp. Vitamin/mineral composition
TW352384B (en) 1992-03-24 1999-02-11 Hoechst Ag Sulfonamido- or sulfonamidocarbonylpyridine-2-carboxamides, process for their preparation and their use as pharmaceuticals
DE4219158A1 (de) 1992-06-11 1993-12-16 Thomae Gmbh Dr K Biphenylderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
EP0650961B1 (de) 1993-11-02 1997-03-05 Hoechst Aktiengesellschaft Substituierte heterocyclische Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
ES2101420T3 (es) 1993-11-02 1997-07-01 Hoechst Ag Esteres-amidas de acidos carboxilicos heterociclicos sustituidos, su preparacion y su utilizacion como medicamentos.
NZ270267A (en) 1993-12-30 1997-03-24 Hoechst Ag 3-hydroxypyridin-2yl (and -quinolin-2-yl) carboxamide derivatives and pharmaceutical compositions
DE4410480A1 (de) 1994-03-25 1995-09-28 Hoechst Ag Sulfonamidocarbonylpyridin-2-carbonsäureesteramide sowie ihre Pyridin-N-oxide, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE4410423A1 (de) 1994-03-25 1995-09-28 Hoechst Ag Sulfonamidocarbonylpyridin-2-carbonsäureamide sowie ihre Pyridin-N-oxide, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US5789426A (en) 1995-01-20 1998-08-04 Cornell Research Foundation, Inc. Method for the treatment of fibroproliferative disorders by application of inhibitors of protein hydroxylation
DE19535571A1 (de) * 1995-09-14 1997-03-20 Boehringer Mannheim Gmbh Pharmazeutische Kombinationspräparate und deren Verwendung zur Behandlung von Hämodialysepatienten
IL135495A (en) 1995-09-28 2002-12-01 Hoechst Ag Intermediate compounds for the preparation of quinoline-converted amines - 2 - carboxylic acid
JPH09221476A (ja) 1995-12-15 1997-08-26 Otsuka Pharmaceut Co Ltd 医薬組成物
WO1997041103A1 (de) 1996-04-30 1997-11-06 Hoechst Aktiengesellschaft 3-alkoxypyridin-2-carbonsäureamidester, ihre herstellung und ihre verwendung als arzneimittel
DE19620041A1 (de) 1996-05-17 1998-01-29 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten
DE19650215A1 (de) 1996-12-04 1998-06-10 Hoechst Ag 3-Hydroxypyridin-2-carbonsäureamidester, ihre Herstellung und ihre Verwendung als Arzneimittel
EP1024134A4 (en) 1997-10-09 2003-05-14 Ono Pharmaceutical Co DERIVATIVES OF AMINOBUTANIC ACID
DE19746287A1 (de) 1997-10-20 1999-04-22 Hoechst Marion Roussel De Gmbh Substituierte Isochinolin-2-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
ATE273277T1 (de) 1998-03-23 2004-08-15 Aventis Pharma Inc Piperidinyl- und n-amidinopiperidinyl-derivate
GB9809213D0 (en) * 1998-04-29 1998-07-01 Glaxo Group Ltd Pharmaceutical compositions
DK1083885T3 (da) 1998-06-11 2007-02-26 Pharmacia & Upjohn Co Llc Delavirdintabletformulering
US6159379A (en) 1999-05-04 2000-12-12 Baker Hughes Incorporated Organic ammonium salts for the removal of water soluble organics in produced water
JP2001048786A (ja) 1999-08-05 2001-02-20 Yamanouchi Pharmaceut Co Ltd 三環式ヘテロアリール誘導体
US6589758B1 (en) 2000-05-19 2003-07-08 Amgen Inc. Crystal of a kinase-ligand complex and methods of use
ATE508738T1 (de) 2001-01-12 2011-05-15 Sun Pharma Advanced Res Co Ltd System zur beabstandeten abgabe von arzneimitteln
US6855510B2 (en) 2001-03-20 2005-02-15 Dana Farber Cancer Institute, Inc. Pharmaceuticals and methods for treating hypoxia and screening methods therefor
US6849718B2 (en) 2001-03-20 2005-02-01 Dana Farber Cancer Institute, Inc. Muteins of hypoxia inducible factor alpha and methods of use thereof
JP4590157B2 (ja) 2001-03-21 2010-12-01 アイシス イノヴェイション リミテッド アッセイ、方法および手段
SE0101327D0 (sv) 2001-04-12 2001-04-12 Astrazeneca Ab New crystalline forms
US6566088B1 (en) 2001-10-04 2003-05-20 Board Of Regents, The University Of Texas System Prolyl-4-hydroxylases
GB0124941D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
CN102552263A (zh) 2001-12-06 2012-07-11 法布罗根股份有限公司 提高内源性红细胞生成素(epo)的方法
EP1556033A4 (en) 2002-05-17 2006-05-31 Celgene Corp METHODS AND COMPOSITIONS USING CYTOKINE INHIBITOR SELECTIVE MEDICAMENTS FOR THE TREATMENT AND MANAGEMENT OF CANCERS AND OTHER DISEASES
WO2003101431A1 (en) * 2002-06-04 2003-12-11 J.B. Chemicals & Pharmaceuticals Ltd. Pharmaceutical composition for controlled drug delivery system
WO2004019868A2 (en) 2002-08-29 2004-03-11 Merck & Co., Inc. N-biarylmethyl aminocycloalkanecarboxamide derivatives
WO2004035812A2 (en) 2002-10-16 2004-04-29 Isis Innovation Limited Asparaginyl hydroxylases and modulators thereof
CA2506799A1 (en) 2002-11-21 2004-06-10 Eli Lilly And Company Mixed lineage kinase modulators
US7618940B2 (en) 2002-12-06 2009-11-17 Fibrogen, Inc. Fat regulation
US8124582B2 (en) 2002-12-06 2012-02-28 Fibrogen, Inc. Treatment of diabetes
US7183287B2 (en) 2003-04-03 2007-02-27 Pharmacia Corporation Substituted pyrimidinones
CA2528232C (en) 2003-06-06 2010-05-25 Fibrogen, Inc. Novel nitrogen-containing heteroaryl compounds and their use in increasing endogenous erythropoietin
WO2005007192A2 (en) 2003-06-06 2005-01-27 Fibrogen, Inc. Cytoprotection through the use of hif hydroxylase inhibitors
US8614204B2 (en) * 2003-06-06 2013-12-24 Fibrogen, Inc. Enhanced erythropoiesis and iron metabolism
GB0314129D0 (en) 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
DE602005016800D1 (de) 2004-05-28 2009-11-05 Fibrogen Inc Hif-prolylhydroxylase-aktivitätstest
JP2008500951A (ja) 2004-05-31 2008-01-17 田辺三菱製薬株式会社 二環化合物
EP1771169A1 (en) 2004-07-14 2007-04-11 PTC Therapeutics, Inc. Methods for treating hepatitis c
WO2006010920A1 (en) * 2004-07-30 2006-02-02 Isis Innovation Limited Soluble polypeptide
TW200616969A (en) 2004-09-17 2006-06-01 Tanabe Seiyaku Co Imidazole compound
WO2006084210A2 (en) 2005-02-04 2006-08-10 Regents Of The University Of California, San Diego Hif modulating compounds and methods of use thereof
DE102005019712A1 (de) 2005-04-28 2006-11-09 Bayer Healthcare Ag Dipyridyl-dihydropyrazolone und ihre Verwendung
US20060276477A1 (en) 2005-06-06 2006-12-07 Fibrogen, Inc. Treatment method for anemia
AU2006259352A1 (en) 2005-06-15 2006-12-28 Fibrogen, Inc. Use of HIF 1alfa modulators for treatment of cancer
WO2007033216A2 (en) 2005-09-12 2007-03-22 Beth Israel Deaconess Medical Center Methods and compositions for the treatment and diagnosis of diseases characterized by vascular leak, hypotension, or a procoagulant state
PT1928409E (pt) 2005-09-12 2012-11-27 Actelion Pharmaceuticals Ltd Composição farmacêutica estável que compreende uma pirimidina-sulfamida
WO2007038571A2 (en) 2005-09-26 2007-04-05 Smithkline Beecham Corporation Prolyl hydroxylase antagonists
US20090176726A1 (en) 2005-10-11 2009-07-09 Fisher David E Methods for treating mitf-related disorders
JP5202327B2 (ja) 2005-12-09 2013-06-05 アムジエン・インコーポレーテツド プロリルヒドロキシラーゼ阻害活性を示すキノロンベースの化合物、およびこの組成物、およびこの使用
GB2453819A (en) 2006-01-09 2009-04-22 Btg Int Ltd Modulators of hypoxia inducible factor-1 and related uses
WO2007082899A1 (en) 2006-01-17 2007-07-26 Vib Vzw Inhibitors of prolyl-hydroxylase 1 for the treatment of skeletal muscle degeneration
JP4801451B2 (ja) 2006-01-19 2011-10-26 株式会社日立ハイテクノロジーズ 走査電子顕微鏡等に用いる電子銃の制御装置及び制御方法
US20070208053A1 (en) 2006-01-19 2007-09-06 Arnold Lee D Fused heterobicyclic kinase inhibitors
ITMI20060179A1 (it) 2006-02-02 2007-08-03 Abiogen Pharma Spa Procedimento per la risoluzione di miscele racemiche e complesso diastereoisomerico di un agente risolvente e di unantiomero di interesse
WO2007101204A1 (en) 2006-02-27 2007-09-07 Alcon Research, Ltd. Method of treating glaucoma
US7588924B2 (en) 2006-03-07 2009-09-15 Procter & Gamble Company Crystal of hypoxia inducible factor 1 alpha prolyl hydroxylase
AR059733A1 (es) 2006-03-07 2008-04-23 Smithkline Beecham Corp Compuesto derivado de glicina n- sustituida con heteroaromaticos bicicicos, composicion farmaceutica que lo comprende, uso para preparar un medicamento para tratar la anemia y proceso para su preparacion
WO2007136990A2 (en) 2006-05-16 2007-11-29 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
KR100798730B1 (ko) * 2006-06-12 2008-01-29 신풍제약주식회사 록소프로펜 또는 잘토프로펜 함유 제어방출성 제제 및 그의제조방법
JO2934B1 (en) 2006-06-23 2015-09-15 سميث كلاين بيتشام كوربوريشن Prolyl hydroxylase inhibitors
BRPI0713350B1 (pt) * 2006-06-26 2022-04-12 Akebia Therapeutics Inc Composto, e, composição
CA2563690C (en) 2006-10-12 2014-10-07 Pharmascience Inc. Pharmaceutical compositions comprising intra- and extra- granular fractions
GB2444904B (en) 2006-12-05 2008-11-05 Michael Hilary Burke A Process For The Preparation of an Orally Administrable Unit Dose Tablet
TW200845991A (en) 2007-01-12 2008-12-01 Smithkline Beecham Corp N-substituted glycine derivatives: hydroxylase inhibitors
CL2008000065A1 (es) 2007-01-12 2008-09-22 Smithkline Beecham Corp Compuestos derivados de glicina n-sustituida, inhibidores de hif prolil hidroxilasas; su proceso de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de la anemia.
EP2134326B1 (en) 2007-04-17 2011-11-16 Ratiopharm GmbH Pharmaceutical compositions comprising irbesartan
CA2683758A1 (en) 2007-04-18 2008-10-30 Merck & Co., Inc. Novel 1,8-naphthyridine compounds
EP2155680B1 (en) 2007-04-18 2013-12-04 Amgen, Inc Indanone derivatives that inhibit prolyl hydroxylase
ES2389063T3 (es) 2007-05-04 2012-10-22 Amgen, Inc Derivados de tienopiridina y tiazolopiridina que inhiben la actividad prolil hidroxilasa
EP2160187B1 (en) 2007-05-16 2013-05-22 Merck Sharp & Dohme Corp. Spiroindalones
CA2687306A1 (en) 2007-05-18 2008-11-27 Bayer Schering Pharma Aktiengesellschaft Heteroaryl substituted pyrazole derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
EP2186528B1 (en) 2007-08-06 2014-03-19 Senju Pharmaceutical Co., Ltd. Pharmaceutical containing hif-1 alpha and hif-2 alpha expression inhibitor
TW200908984A (en) 2007-08-07 2009-03-01 Piramal Life Sciences Ltd Pyridyl derivatives, their preparation and use
CA2696725A1 (en) 2007-08-10 2009-03-26 Crystalgenomics, Inc. Pyridine derivatives and methods of use thereof
WO2009035534A2 (en) 2007-09-07 2009-03-19 The Cleveland Clinic Foundation Treatment of ischemic eye disease by the systematic pharmaceutical activation of hypoxia inducible factor (hif)
WO2009039323A1 (en) 2007-09-19 2009-03-26 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
WO2009039321A1 (en) 2007-09-19 2009-03-26 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
WO2009043093A1 (en) 2007-10-04 2009-04-09 Newsouth Innovations Pty Limited Hif inhibition
WO2009049112A1 (en) 2007-10-10 2009-04-16 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
DE102008039959A1 (de) 2007-11-19 2009-05-20 Continental Teves Ag & Co. Ohg Druckregelventil
WO2009067790A1 (en) 2007-11-26 2009-06-04 Uti Limited Partnership STIMULATION OF HYPOXIA INDUCIBLE FACTOR -1 ALPHA (HIF-1α) FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE ASSOCIATED DISEASE (CDAD), FOR INTESTINAL MOTILITY AND FOR DETECTING INFECTION
WO2009070644A1 (en) 2007-11-30 2009-06-04 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
US20100305133A1 (en) 2007-11-30 2010-12-02 Smithkline Beecham Corporation Prolyl Hydroxylase Inhibitors
US8269008B2 (en) 2007-12-03 2012-09-18 Fibrogen, Inc. Oxazolopyridine and isoxazolopyridine derivatives for use in the treatment of HIF-mediated conditions
WO2009086044A1 (en) 2007-12-19 2009-07-09 Smith Kline Beecham Corporation Prolyl hydroxylase inhibitors
WO2009086592A1 (en) 2008-01-04 2009-07-16 Garvan Institute Of Medical Research Method of increasing metabolism
EP2252619B1 (en) 2008-01-11 2013-10-09 Fibrogen, Inc. Isothiazole-pyridine derivatives as modulators of hif (hypoxia inducible factor) activity
PT2268618E (pt) 2008-03-03 2015-10-12 Novartis Ag Compostos e composições moduladores da actividade tlr
PE20110409A1 (es) 2008-07-23 2011-06-22 Hoffmann La Roche Compuestos heterociclicos antiviricos
TW201006473A (en) * 2008-08-13 2010-02-16 Orient Pharma Co Ltd Bi-layer medicine tablet containing Zaleplon
JP2012502900A (ja) 2008-09-15 2012-02-02 カシナ ライラ イノバ ファーマシューティカルズ プライベート リミテッド 抗癌剤並びにそれに関する転移性悪性黒色腫及び他の癌についての使用
HU230877B1 (hu) * 2008-09-30 2018-11-29 EGIS Gyógyszergyár NyR Stabil kombinációs gyógyszerkészítmény
WO2010056767A1 (en) 2008-11-14 2010-05-20 Fibrogen, Inc. Thiochromene derivatives as hip hydroxylase inhibitors
US8137666B2 (en) 2008-11-22 2012-03-20 Academia Sinica Nattokinase for degrading and reducing amyloid fibrils—associated with alzheimer's disease, prion diseases and other amyloidoses
SI2415771T1 (sl) 2009-03-31 2013-12-31 Kissei Pharmaceutical Co., Ltd. Derivat indolizina in njegova uporaba v medicinske namene
EP3708163A1 (en) 2009-03-31 2020-09-16 Ligand Pharmaceuticals, Inc. Use of sparsentan for the treatment of chronic inflammatory diseases
SI2455381T1 (sl) 2009-07-17 2014-08-29 Japan Tobacco Inc. Triazolopiridinova spojina in njeno delovanje kot zaviralec prolil-hidroksilaze in induktor produkcije eritropoietina
EP3698794A1 (en) 2009-11-06 2020-08-26 Aerpio Therapeutics, Inc. Compositions and methods for treating colitis
WO2012097331A1 (en) 2011-01-13 2012-07-19 Fibrogen, Inc. Methods for increasing reticulocyte hemoglobin content
NO2686520T3 (https=) 2011-06-06 2018-03-17
EP2717870B1 (en) 2011-06-06 2017-09-27 Akebia Therapeutics Inc. Composition for stabilizing hypoxia inducible factor-2 alpha useful for treating cancer
US20130022974A1 (en) 2011-06-17 2013-01-24 The Regents Of The University Of Michigan Dna methylation profiles in cancer
US9206134B2 (en) 2011-07-22 2015-12-08 Beijing Betta Pharmaceuticals Co. Ltd. Polymorphic forms of compounds as prolyl hydroxylase inhibitor, and uses thereof
EP2983674A4 (en) 2013-04-08 2017-05-10 Dennis M. Brown Therapeutic benefit of suboptimally administered chemical compounds
SG10201910773VA (en) 2013-06-13 2020-01-30 Akebia Therapeutics Inc Compositions and methods for treating anemia
RU2016109125A (ru) 2013-08-16 2017-09-22 Огайо Стейт Инновейшн Фаундейшн Композиции и способы модуляции метилирования днк
AR099354A1 (es) 2013-11-15 2016-07-20 Akebia Therapeutics Inc Formas sólidas de ácido {[5-(3-clorofenil)-3-hidroxipiridin-2-carbonil]amino}acético, composiciones, y sus usos
WO2015112831A1 (en) 2014-01-23 2015-07-30 Akebia Therapeutics, Inc. Compositions and methods for treating ocular diseases
AU2016209126A1 (en) 2015-01-23 2017-08-10 Akebia Therapeutics, Inc. Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof
US20180065933A1 (en) 2015-03-20 2018-03-08 Akebia Therapeutics, Inc. Deuterium-enriched hypoxia-inducible factor prolyl hydroxylase enzyme inhibitors
US11324734B2 (en) 2015-04-01 2022-05-10 Akebia Therapeutics, Inc. Compositions and methods for treating anemia
WO2019028150A1 (en) 2017-08-01 2019-02-07 Akebia Therapeutics, Inc. COMPOSITIONS FOR USE IN METHODS OF TREATING HEMOGLOBINOPATHIES
US20210369678A1 (en) 2018-10-03 2021-12-02 Akebia Therapeutics, Inc. Benzimidazole derivative for use in the treatment of inflammatory disorders
US11524939B2 (en) * 2019-11-13 2022-12-13 Akebia Therapeutics, Inc. Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid

Also Published As

Publication number Publication date
MX2015017229A (es) 2016-04-19
BR112015031027A2 (pt) 2017-08-29
TW202446394A (zh) 2024-12-01
EP3007695B1 (en) 2024-02-07
HK1216844A1 (en) 2016-12-09
IL243047B (en) 2019-11-28
EP4360706A2 (en) 2024-05-01
CY1126699T1 (el) 2025-05-09
JP2016521747A (ja) 2016-07-25
RU2016100363A (ru) 2017-07-18
CY2024016I1 (el) 2025-05-09
ES2974273T3 (es) 2024-06-26
JP2025114609A (ja) 2025-08-05
KR20240055172A (ko) 2024-04-26
JP6937812B2 (ja) 2021-09-22
JP2023145717A (ja) 2023-10-11
CL2015003602A1 (es) 2016-07-29
AU2024205219A1 (en) 2024-09-19
NL301278I2 (nl) 2024-08-01
FI3007695T3 (fi) 2024-03-13
IL281058B1 (en) 2023-04-01
US20240335434A1 (en) 2024-10-10
MX391198B (es) 2025-03-21
RS65341B1 (sr) 2024-04-30
PH12015502738B1 (en) 2021-12-10
KR20220151008A (ko) 2022-11-11
TWI712411B (zh) 2020-12-11
IL281058B2 (en) 2023-08-01
KR20210043760A (ko) 2021-04-21
EP3007695A4 (en) 2017-05-31
TW202133843A (zh) 2021-09-16
WO2014200773A2 (en) 2014-12-18
JP7672455B2 (ja) 2025-05-07
SG10201910773VA (en) 2020-01-30
RU2016100363A3 (https=) 2018-05-15
RU2705206C2 (ru) 2019-11-06
MX2022003510A (es) 2022-05-16
JP2021191773A (ja) 2021-12-16
EP3007695A2 (en) 2016-04-20
NZ753905A (en) 2020-07-31
JP6612479B2 (ja) 2019-11-27
DK3007695T3 (da) 2024-03-18
DOP2015000297A (es) 2016-03-15
CN105451739A (zh) 2016-03-30
CY2024016I2 (el) 2025-05-09
KR102660040B1 (ko) 2024-04-24
RU2019134558A (ru) 2020-02-20
NZ753904A (en) 2020-07-31
EP4360706A3 (en) 2024-07-10
MY204336A (en) 2024-08-23
HRP20240319T1 (hr) 2024-05-24
PL3007695T3 (pl) 2024-07-01
US20160143891A1 (en) 2016-05-26
KR102373245B1 (ko) 2022-03-17
KR102461176B1 (ko) 2022-11-01
TWI650126B (zh) 2019-02-11
LTPA2024521I1 (https=) 2024-07-10
AU2014278543A1 (en) 2016-01-07
TW201922244A (zh) 2019-06-16
AU2022200570A1 (en) 2022-02-17
AU2020200903A1 (en) 2020-02-27
SMT202400092T1 (it) 2024-05-14
CA2914662A1 (en) 2014-12-18
FR24C1025I2 (fr) 2025-06-20
TWI791177B (zh) 2023-02-01
MX378150B (es) 2025-03-10
TWI856464B (zh) 2024-09-21
CL2018002372A1 (es) 2018-12-28
KR20160023773A (ko) 2016-03-03
FIC20240023I1 (fi) 2024-06-25
JP7328291B2 (ja) 2023-08-16
TW201534302A (zh) 2015-09-16
HUE066123T2 (hu) 2024-07-28
NZ714963A (en) 2020-07-31
WO2014200773A3 (en) 2015-03-05
PE20160194A1 (es) 2016-04-20
SG11201509998WA (en) 2016-01-28
IL281058A (en) 2021-04-29
TW202339743A (zh) 2023-10-16
LT3007695T (lt) 2024-03-25
ECSP20058592A (es) 2020-10-30
FR24C1025I1 (fr) 2024-07-26
PH12015502738A1 (en) 2016-03-07
MX2020006963A (es) 2022-03-30
SI3007695T1 (sl) 2024-04-30
PE20201496A1 (es) 2020-12-29
JP2019163293A (ja) 2019-09-26
AU2020200903B2 (en) 2021-11-04
JP2020033369A (ja) 2020-03-05
NO2024025I1 (no) 2024-05-29
US11857543B2 (en) 2024-01-02
PH12020551705A1 (en) 2021-11-15
CA3151685A1 (en) 2014-12-18
US12569474B2 (en) 2026-03-10
IL270335B (en) 2021-03-25
CN114404414A (zh) 2022-04-29
AU2022200570B2 (en) 2024-05-02
CN114404413A (zh) 2022-04-29
ZA201509024B (en) 2019-05-29
AU2014278543B2 (en) 2019-11-14
PT3007695T (pt) 2024-03-07
HUS2400023I1 (hu) 2024-07-28

Similar Documents

Publication Publication Date Title
US12569474B2 (en) Compositions and methods for treating anemia
HK40109871A (en) Compositions and methods for treating anemia
HK1216844B (en) Compositions and methods for treating anemia

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20190510

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 11TH ANNIV.) - STANDARD

Year of fee payment: 11

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250513

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250513